Glenmark Pharmaceuticals Limited has submitted to the Exchange, Unaudited Financial Results (Standalone and Consolidated) for the Second Quarter and Half Yearended 30th September, 2025.

Results View source PDF Explain this filing

GLENMARK · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.5%Reaction day

₹1895.00

prior close

₹1855.10

announcement price

After-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)+0.7%-2.1% vs market

Pharmaceuticals peers, median of 157sector+0.1%-1.5% vs sector

On the reaction day the stock moved 2.1 pts less than Nifty Midcap 150 and 1.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.7

10m

-0.6

15m

-0.6

30m

+1.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.5+0.7-2.1+0.1-1.5

Next day

-3.2+0.1-3.2-0.7-2.5

-2.8+0.4-3.2-1.1-1.8

-0.5+0.3-0.9-0.9+0.4

-2.7-0.8-1.9-1.9-0.8

-3.1-1.1-2.0-3.2+0.0

+1.3+0.4+0.9-2.2+3.5

15d

+1.3-2.2+3.6-4.8+6.1

+2.4-2.2+4.6-5.2+7.6

+4.8-2.0+6.8-7.8+12.6

+7.3-1.3+8.6-9.7+17.0

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Glenmark Pharmaceuticals has filed its unaudited financial results for the second quarter and first half of the financial year ending 30th September 2025 with the stock exchange. The filing covers both standalone and consolidated numbers. The actual financial figures are contained in the attached results document and not in the announcement text itself. This is a routine quarterly compliance filing under SEBI listing regulations.

Likely market impact

No direct impact from this announcement alone — investors should review the detailed results document for revenue, profit, and margin trends to assess the company's quarterly performance.